GW&K Investment Management LLC boosted its position in shares of Catalent Inc (NYSE:CTLT) by 13.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,010,273 shares of the company’s stock after purchasing an additional 235,371 shares during the period. Catalent comprises about 1.3% of GW&K Investment Management LLC’s investment portfolio, making the stock its 3rd biggest position. GW&K Investment Management LLC’s holdings in Catalent were worth $95,810,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in CTLT. Magnetar Financial LLC raised its stake in shares of Catalent by 340.9% in the second quarter. Magnetar Financial LLC now owns 104,480 shares of the company’s stock worth $5,664,000 after acquiring an additional 80,782 shares during the last quarter. Bailard Inc. acquired a new position in shares of Catalent in the 2nd quarter valued at about $379,000. Virginia Retirement Systems ET AL lifted its holdings in shares of Catalent by 19.3% in the 2nd quarter. Virginia Retirement Systems ET AL now owns 22,300 shares of the company’s stock valued at $1,209,000 after buying an additional 3,600 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Catalent by 2.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,553,474 shares of the company’s stock valued at $84,214,000 after buying an additional 32,691 shares during the period. Finally, Global Thematic Partners LLC acquired a new position in shares of Catalent in the 2nd quarter valued at about $5,539,000.
Shares of CTLT traded up $0.27 during midday trading on Friday, reaching $49.52. 467,188 shares of the stock were exchanged, compared to its average volume of 806,017. The business’s 50-day moving average price is $49.09 and its 200 day moving average price is $50.57. The company has a debt-to-equity ratio of 2.74, a current ratio of 2.06 and a quick ratio of 1.70. Catalent Inc has a twelve month low of $29.23 and a twelve month high of $58.38. The company has a market capitalization of $7.38 billion, a price-to-earnings ratio of 30.57, a PEG ratio of 2.47 and a beta of 1.69.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.07. Catalent had a return on equity of 16.87% and a net margin of 5.77%. The business had revenue of $664.70 million for the quarter, compared to analysts’ expectations of $634.87 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The business’s revenue was up 20.5% compared to the same quarter last year. As a group, equities research analysts expect that Catalent Inc will post 1.81 earnings per share for the current fiscal year.
In related news, CEO John R. Chiminski sold 97,043 shares of the firm’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $48.84, for a total transaction of $4,739,580.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gregory T. Lucier purchased 2,000 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average cost of $51.64 per share, for a total transaction of $103,280.00. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.
A number of research firms have weighed in on CTLT. UBS Group raised their price target on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Morgan Stanley raised their price target on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, August 28th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Stephens began coverage on Catalent in a research note on Thursday, October 17th. They issued an “overweight” rating and a $56.00 price target on the stock. Finally, Robert W. Baird raised their price target on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Catalent currently has a consensus rating of “Buy” and an average price target of $56.25.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.